Salvage high dose-rate brachytherapy for local recurrence of prostate cancer after different types of radical treatment
https://doi.org/10.17650/1726-9776-2019-15-2-73-76
Abstract
Objective: at the primary analysis of prostate cancer treatment referring to the patients who have experienced high dose rate brachytherapy after a confirmed locally recurrent tumor having been treated with diverse treatment modes.
Materials and methods. The research includes 28 patients aged 53 to 78 years old (average age is 66 years old) with histologically verified prostate cancer recurrence. Within the period 2015–2017 all the patients got a salvage high dose rate brachytherapy in the Russian Scientific Center of Roentgenradiology. Brachytherapy was carried out as 2 fractions with the single tumor dose of 12.5 Gy. There was a two-week gap between fractions with the total tumor dose of 25 Gy. The follow-up period is 9 to 36 months.
Results and conclusion. Overall biochemical free survival rate is 82.1 %. There are 5 people having a growing prostatic specific antigen (PSA) while the case follow-up. There is 1 case of a confirmed local tumor recurrence. Significant factors of the disease progression after salvage brachytherapy are: risk group, pretreatment PSA high, time line from the background therapy to biochemical recurrence uprise and PSA level if there’s prostate cancer recurrence after the background therapy.
About the Authors
V. A. Solodkiy
Russian Scientific Center of Roentgenradiology, Ministry of Health of Russia
Russian Federation
Russian Federation
86 Profsoyuznaya St., Moscow 117997
A. Yu. Pavlov
Russian Scientific Center of Roentgenradiology, Ministry of Health of Russia
Russian Federation
Russian Federation
86 Profsoyuznaya St., Moscow 117997
A. D. Tsybulskiy
Russian Scientific Center of Roentgenradiology, Ministry of Health of Russia
Russian Federation
Russian Federation
86 Profsoyuznaya St., Moscow 117997
A. G. Dzidzariya
Russian Scientific Center of Roentgenradiology, Ministry of Health of Russia
Russian Federation
Russian Federation
86 Profsoyuznaya St., Moscow 117997
A. S. Pchelintsev
Russian Scientific Center of Roentgenradiology, Ministry of Health of Russia
Russian Federation
Russian Federation
86 Profsoyuznaya St., Moscow 117997
References
1. Liu J., Kaidu M., Sasamoto R. et al. Two-fraction high-dose-rate brachytherapy within a single day combined with external beam radiotherapy forprostate cancer: single institution experience and outcomes. J Radiat Res 2016;57(3):280–7. DOI: 10.1093/jrr/rrw003.
2. Gabriele D., Jereczek-Fossa B.A., Krengli M. et al. Beyond D’Amico risk classes for predicting recurrence after external beam radiotherapy for prostate cancer: the Candiolo classifier. Radiat Oncol 2016;11(1):23. DOI: 10.1186/s13014-0160599-5.
3. Olarte A., Cambeiro M., Moreno-Jiménez M. et al. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes. Brachytherapy 2016;15(2):127–35. DOI: 10.1016/j.brachy.2015.12.008.
4. Garibaldi E., Gabriele D., Maggio A. et al. External beam radiotherapy with dose escalation in 1080 prostate cancer patients: definitive outcome and dose impact. Panminerva Med 2016;58(2):121–9.
5. Bolla M., Van Tienhoven G., Warde P. et al. External irradiation with or without longterm androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomized study. Lancet Oncol 2010;11(11):1066–73. DOI: 10.1016/S1470-2045(10)70223-0.
6. Jo Y., Fujii T., Hara R. et al. Salvage high-dose-rate brachytherapy for local prostate cancer recurrence after radiotherapy – preliminary results. BJU Int 2012;109(6):835–9. DOI: 10.1111/j.1464-410X.2011.10519.x.
7. Matei D.V., Ferro M., Jereczek-Fossa B.A. et al. Radical prostatectomy after external beam radiation therapy: a systematic review of current approaches. Urol Int 2015;94(4):373– 82. DOI: 10.1159/000371893.
8. Berlin A., Fernandez M.I. Avances en el tratamiento de cancer de prostata resistente a la castracion: enfasis en nuevas terapias hormonales. Rev Méd Chile 2015;2:143–9.
9. Grado G.L., Collins J.M., Kriegshauser J.S. et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999;53(1):2–10.
10. Aaronson D.S., Yamasaki I., Gottschalk A. et al. Salvage permanent perineal radioactiveseed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy. BJU Int 2009;104(5):600–4. DOI: 10.1111/j.1464-410X.2009.08445.x.
11. Lee B., Shinohara K., Weinberg V. et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California, San Francisco experience. Int J Radiat Oncol Biol Phys 2007;67(4):1106–12. DOI: 10.1016/j.ijrobp.2006.10.012.
12. Morton J., Loblaw G., D’Alimonte A. et al. Focal Salvage high dose-rate brachytherapy for locally recurrent prostate cancer after primary radiotherapy failure: results from a prospective clinical trial. Int J Rad Oncol Biol Phys 2018;102 (3):33–40.
13. Kollmeier M.A., McBride S., Taggar A. et al. Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: a comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time. Brachytherapy 2017;16(6): 1091–8. DOI: 10.1016/j.brachy.2017.07.013.
Review
For citations:
Solodkiy V.A., Pavlov A.Yu., Tsybulskiy A.D., Dzidzariya A.G., Pchelintsev A.S. Salvage high dose-rate brachytherapy for local recurrence of prostate cancer after different types of radical treatment. Cancer Urology. 2019;15(2):73-76. (In Russ.) https://doi.org/10.17650/1726-9776-2019-15-2-73-76
Views:
1376
Email this article 